°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

¹Ì±¹ÀÇ ¸Á¸· Ä¡·á ½ÃÀå : ºÐ±âº° ¾÷µ¥ÀÌÆ®

US Retina Market Quarterly Updates

¸®¼­Ä¡»ç Market Scope, LLC
¹ßÇàÁ¤º¸ 4 ȸ/³â »óǰ ÄÚµå 644709
ÆäÀÌÁö Á¤º¸ ¿µ¹®
°¡°Ý
US $ 11,350 £Ü 12,828,000 Annual Subscription (Single User License)
US $ 17,000 £Ü 19,215,000 Annual Subscription (Enterprise License)


¹Ì±¹ÀÇ ¸Á¸· Ä¡·á ½ÃÀå : ºÐ±âº° ¾÷µ¥ÀÌÆ® US Retina Market Quarterly Updates
¹ßÇàÁ¤º¸ : 4 ȸ/³â ÆäÀÌÁö Á¤º¸ : ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ ¸Á¸· Ä¡·á(Retinal Procedures) ½ÃÀåÀÇ ÁÖ¿ä ¸ÞÆ®¸¯½º¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Ä¡·áÁ¦(Lucentis, Avastin, Eylea)ÀÇ »ç¿ë, À¯¸®Ã¼³»(IVT) ÁÖ»ç, ´ç´¢º´¼º Ȳ¹ÝºÎÁ¾(DME)ÀÇ Ä¡·á, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ »ç¿ë, ±¤ÀÀ°í ¼ö¼ú °Ç¼ö¿Í ±¤ÀÀ°íÀåÄ¡ÀÇ »ç¿ë, À¯¸®Ã¼ ÀýÁ¦ °Ç¼ö¿Í À§Ä¡, ÀÏȸ¿ë ¼ö¼ú¿ë ÆÑ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

  • °³¿ä
  • ȯÀÚ Áø´Ü
  • IVT ÁÖ»ç(À¯¸®Ã¼³» ÁÖ»ç) : Á¾·ù ¹× Áø´Üº°
  • AMDÀÇ Ä¡·á ¼±ÅÃ
  • Ç×VEGF¿¡ ÀÇÇÑ VA ȹµæ
  • º´¿ë¿ä¹ýÀÇ »ç¿ë : Á¾·ùº°
  • ´ç´¢º´¼º Ȳ¹ÝºÎÁ¾ÀÇ Ä¡·á ¼±ÅÃ
  • À¯¸®Ã¼ ÀýÁ¦¼ú °Ç¼ö : Àǻ纰
  • À¯¸®Ã¼ ÀýÁ¦ ÀÌÀ¯
  • °¡½ÃÈ­Á¦
  • ¼ö¼ú À§Ä¡
  • À¯¸®Ã¼ ÀýÁ¦ ¸Ó½Å
  • À¯¸®Ã¼ ÀýÁ¦ ½Ã½ºÅÛ ±¸ÀÔ °èȹ
  • À¯¸®Ã¼ ÀýÁ¦ ±â±¸ÀÇ ÃøÁ¤
  • ¾È³» ŽÆ÷³×À̵åÁ¦
  • ±¤ÀÀ°í ¼ö¼ú
  • ·¹ÀÌÀú ³»½Ã°æ Á¦Á¶¾÷ü
  • »ç¿ë ±¤ÀÀ°íÁ¦
  • ¸Á¸· ¼ö¼ú Á¦Ç°
  • ÀÏȸ¿ë ¼ö¼ú¿ë ÆÑ
  • ÀçÀÌ¿ë °¡´É vs. ÀÏȸ¿ë ±â±¸·ù
  • ¿¬°£ ¿¹Ãø ¹× Àü³âµµ¿ÍÀÇ ºñ±³
KSM 18.06.11

We collect data on a quarterly basis from US retina specialists on a range of practice of medicine and practice management issues. We began this survey process in 2008. The data we collect are analyzed and presented in our US Retina Quarterly Updates.

New in 2019 - focus on next-gen vitrectomy machine features and newly approved IVTs, and adoption plans for genetic screening.

KEY METRICS:

  • IVT injections by disease and product;
  • Use of Eylea, Lucentis, Avastin, Ozurdex, and Iluvien;
  • DME treatments;
  • Corticosteroid use;
  • Photocoagulation volume and photocoagulators used;
  • Vitrectomy volume and location;
  • Reusable and disposable instruments;
  • Visualization agents.

Market Scope has been surveying United States ophthalmologists quarterly for over 20 years. The resulting data are analyzed and presented in our Quarterly Update Reports.

This update is designed to improve your decision-making process with an assessment of current market conditions and the identification of significant market trends. Each update includes full-year forecasts, comparisons with prior years, and trend analysis.

OUR PROCESS:

Every quarter, Market Scope surveys 3,500+ doctors from all specialties in order to produce these updates. We survey on procedure volumes, pricing and fees, product preferences, treatment plans, adoption of new technologies, and much more.

Beyond survey data, Market Scope sources additional information from our proprietary disease models, database of refractive and cataract specialists, primary research, and public data sources. In some cases, this additional information is used to extrapolate survey data to total market estimates.

Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q